Embecta Corp (EMBC)vsIntuitive Surgical Inc (ISRG)
EMBC
Embecta Corp
$5.29
+1.93%
HEALTHCARE · Cap: $279.90M
ISRG
Intuitive Surgical Inc
$393.33
+2.55%
HEALTHCARE · Cap: $132.26B
Smart Verdict
WallStSmart Research — data-driven comparison
Intuitive Surgical Inc generates 983% more annual revenue ($11.03B vs $1.02B). ISRG leads profitability with a 28.4% profit margin vs 8.6%. EMBC trades at a lower P/E of 3.4x. ISRG earns a higher WallStSmart Score of 66/100 (B-).
EMBC
Hold43
out of 100
Grade: D
ISRG
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-41.7%
Fair Value
$7.10
Current Price
$5.29
$1.81 premium
Margin of Safety
+79.2%
Fair Value
$1891.90
Current Price
$393.33
$1498.57 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Conservative balance sheet, low leverage
Strong operational efficiency at 23.7%
Strong operational efficiency at 33.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
18.5% revenue growth
Earnings expanding 26.5% YoY
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Revenue declined 8.1%
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : EMBC
The strongest argument for EMBC centers on P/E Ratio, Debt/Equity, Operating Margin.
Bull Case : ISRG
The strongest argument for ISRG centers on Operating Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 28.4% and operating margin at 33.6%. Revenue growth of 18.5% demonstrates continued momentum.
Bear Case : EMBC
The primary concerns for EMBC are Altman Z-Score, Market Cap, Return on Equity.
Bear Case : ISRG
The primary concerns for ISRG are PEG Ratio, P/E Ratio. A P/E of 41.3x leaves little room for execution misses.
Key Dynamics to Monitor
EMBC profiles as a value stock while ISRG is a growth play — different risk/reward profiles.
ISRG carries more volatility with a beta of 1.47 — expect wider price swings.
ISRG is growing revenue faster at 18.5% — sustainability is the question.
ISRG generates stronger free cash flow (948M), providing more financial flexibility.
Bottom Line
ISRG scores higher overall (66/100 vs 43/100), backed by strong 28.4% margins and 18.5% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Embecta Corp
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Embecta Corp (EMBC) is a leading medical technology company specializing in innovative insulin delivery systems aimed at enhancing diabetes management. Born from a spin-off of Becton, Dickinson and Company, Embecta provides a comprehensive portfolio of advanced products, including cutting-edge insulin pens and syringes tailored to improve patient outcomes. With a robust focus on operational excellence and customer satisfaction, Embecta is well-positioned to capitalize on growth opportunities in the rapidly expanding diabetes care market, strengthening its leadership in this vital sector.
Visit Website →Intuitive Surgical Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?